RENB (Renovaro) Additional Paid-In Capital : $471.33 Mil(As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Renovaro Additional Paid-In Capital?

Renovaro's quarterly additional paid-in capital increased from Sep. 2024 ($460.67 Mil) to Dec. 2024 ($469.81 Mil) and increased from Dec. 2024 ($469.81 Mil) to Mar. 2025 ($471.33 Mil).

Renovaro's annual additional paid-in capital increased from Jun. 2022 ($276.99 Mil) to Jun. 2023 ($290.56 Mil) and increased from Jun. 2023 ($290.56 Mil) to Jun. 2024 ($464.59 Mil).

Renovaro Additional Paid-In Capital Historical Data

The historical data trend for Renovaro's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Additional Paid-In Capital Chart

Renovaro Annual Data

Trend

Dec14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Additional Paid-In Capital

Get a 7-Day Free Trial

230.50

265.58

276.99

290.56

464.59

Renovaro Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															442.31	464.59	460.67	469.81	471.33

Renovaro Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Renovaro Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Renovaro's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovaro Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

2Q5:Germany

Address

2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067

Website

https://www.renovarogroup.com

Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.

Executives

Anderson Wittekind William	10 percent owner	8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leni Boeren	director	2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks	director	CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard	10 percent owner	VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette	officer: Executive Vice President	2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu	10 percent owner	2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev	director, 10 percent owner	FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler	other: Former director see note below	330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol	director	606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen	director	STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche	officer: Chief Financial Officer	318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne	director	NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Leire, Eric Jean Marie	director, officer: CEO; President	C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060